Cytosorbents (NASDAQ: CTSO) reported Q2 EPS of ($0.11), $0.07 worse than the analyst estimate of ($0.04). Revenue for the quarter came in at $12 million versus the consensus estimate of $12.27 million.

For earnings history and earnings-related data on Cytosorbents (CTSO) click here.